PMID- 35865339
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230630
IS  - 1741-427X (Print)
IS  - 1741-4288 (Electronic)
IS  - 1741-427X (Linking)
VI  - 2022
DP  - 2022
TI  - The Clinical Effects of Metronidazole Vaginal Effervescent Tablets Combined with 
      Kushen Suppository in the Treatment of Trichomonas Vaginitis.
PG  - 7730474
LID - 10.1155/2022/7730474 [doi]
LID - 7730474
AB  - OBJECTIVE: The aim of this study was to explore the clinical effects of 
      metronidazole vaginal effervescent tablets combined with Kushen suppository in 
      the treatment of Trichomonas vaginitis. METHODS: Ninety patients with 
      trichomoniasis admitted to our hospital from January 2019 to January 2020 were 
      prospectively analyzed and randomly divided into a control group (n = 45) treated 
      with metronidazole vaginal effervescent tablets and an experimental group 
      (n = 45) treated with Kushen suppository on top of the control group using the 
      random number table method. The clinical effects, inflammatory factors, and 
      microcirculation indexes were compared. We assessed patient's vaginal health by 
      Vaginal Health Score Scale (VHS) before and after treatment and estimated their 
      quality of life according to Generic Quality of Life Inventory-74 (GQOLI-74). A 
      follow-up visit was conducted to compare patient's recurrence 3 months after 
      treatment. RESULTS: Distinctly higher total clinical effective of the 
      experimental group compared with that of the control group was obtained (P < 
      0.05); the serum level of inflammatory factors of the experimental group was 
      dramatically lower than that of the control group after treatment (P < 0.001); 
      the experimental group experienced a favorable microcirculation index in 
      comparison with the control group (P < 0.001); superior VHS (P < 0.001) and 
      GQOLI-74 (P < 0.05) scores of the experimental group after treatment compared to 
      those of the control group were observed; the recurrence rate of the experimental 
      group 3 months after treatment was significantly decreased in comparison with 
      that of the control group (P < 0.05). CONCLUSION: Metronidazole vaginal 
      effervescent tablets combined with Kushen suppository can effectively improve the 
      clinical symptoms of patients with trichomonas vaginitis, abate patient's 
      inflammatory reaction, and raise their quality of life, which is worthy of 
      promotion.
CI  - Copyright (c) 2022 Hongxia Zhang et al.
FAU - Zhang, Hongxia
AU  - Zhang H
AD  - Department of Pharmacy, The Fourth Hospital of Shijiazhuang, Shijiazhuang 050000, 
      China.
FAU - Jing, Zeng
AU  - Jing Z
AD  - Department of Pharmacy, The Fourth Hospital of Shijiazhuang, Shijiazhuang 050000, 
      China.
FAU - Li, Feng
AU  - Li F
AD  - Department of Gynecology, The Fourth Hospital of Shijiazhuang, Shijiazhuang 
      050000, China.
FAU - Yue, Benming
AU  - Yue B
AD  - Department of Gynecology, The Fourth Hospital of Shijiazhuang, Shijiazhuang 
      050000, China.
FAU - Zhang, Ping
AU  - Zhang P
AD  - Department of Gynecology, The Fourth Hospital of Shijiazhuang, Shijiazhuang 
      050000, China.
FAU - Li, Hui
AU  - Li H
AUID- ORCID: 0000-0001-5954-4203
AD  - Department of Gynecology, The Fourth Hospital of Shijiazhuang, Shijiazhuang 
      050000, China.
LA  - eng
PT  - Journal Article
PT  - Retracted Publication
DEP - 20220712
PL  - United States
TA  - Evid Based Complement Alternat Med
JT  - Evidence-based complementary and alternative medicine : eCAM
JID - 101215021
RIN - Evid Based Complement Alternat Med. 2023 Jun 21;2023:9898367. PMID: 37388024
PMC - PMC9296293
COIS- All authors declare that they have no conflicts of interest.
EDAT- 2022/07/23 06:00
MHDA- 2022/07/23 06:01
PMCR- 2022/07/12
CRDT- 2022/07/22 02:25
PHST- 2022/05/18 00:00 [received]
PHST- 2022/06/10 00:00 [revised]
PHST- 2022/06/13 00:00 [accepted]
PHST- 2022/07/22 02:25 [entrez]
PHST- 2022/07/23 06:00 [pubmed]
PHST- 2022/07/23 06:01 [medline]
PHST- 2022/07/12 00:00 [pmc-release]
AID - 10.1155/2022/7730474 [doi]
PST - epublish
SO  - Evid Based Complement Alternat Med. 2022 Jul 12;2022:7730474. doi: 
      10.1155/2022/7730474. eCollection 2022.